Critical Reviews in Oncology / Hematology
Volume 75, Issue 2 , Pages 79-93 , August 2010

Abnormal immunity and stem/progenitor cells in acquired aplastic anemia

  • Jian Ping Li
    • ,
  • Cui Ling Zheng
    • ,
  • Zhong Chao Han

      Affiliations

    • Corresponding Author InformationCorresponding author at: State Key Laboratory of Experimental Hematology, National Research Center for Stem Cell Engineering and Technology, Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, PR China. Tel.: +86 22 27210717; fax: +86 22 66211430.

,Accepted 9 December 2009.

References 

  1. Shimamura A. Inherited bone marrow failure syndromes: molecular features. Hematology (Am Soc Hematol Educ Program). 2006;63–71
  2. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–2519
  3. Morley A, Blake J. An animal model of chronic aplastic marrow failure. I. Late marrow failure after busulfan. Blood. 1974;44:49–56
  4. Knospe WH, Crosby WH. Aplastic anaemia: a disorder of the bone-marrow sinusoidal microcirculation rather than stem-cell failure?. Lancet. 1971;1:20–22
  5. Pugsley CA, Forbes IJ, Morley AA. Immunologic abnormalities in an animal model of chronic hypoplastic marrow failure induced by busulfan. Blood. 1978;51:601–610
  6. Steiner RM, Mitchell DG, Rao VM, Murphy S, Rifkin MD, Burk DL, et al. Magnetic resonance imaging of bone marrow: diagnostic value in diffuse hematologic disorders. Magn Reson Q. 1990;6:17–34
  7. Negendank W, Weissman D, Bey TM, de Planque MM, Karanes C, Smith MR, et al. Evidence for clonal disease by magnetic resonance imaging in patients with hypoplastic marrow disorders. Blood. 1991;78:2872–2879
  8. Elghetany MT, Hudnall SD, Gardner FH. Peripheral blood picture in primary hypocellular refractory anemia and idiopathic acquired aplastic anemia: an additional tool for differential diagnosis. Haematologica. 1997;82:21–24
  9. Keidan AJ, Tsatalas C, Cohen J, Cousins S, Gordon-Smith EC. Infective complications of aplastic anaemia. Br J Haematol. 1986;63:503–508
  10. Twomey JJ, Douglass CC, Sharkey O. The monocytopenia of aplastic anemia. Blood. 1973;41:187–195
  11. Gascon P, Zoumbos N, Young N. Analysis of natural killer cells in patients with aplastic anemia. Blood. 1986;67:1349–1355
  12. Porwit A, Hast R, Stenke L, Wasserman J, Reizenstein P. Decreased blood natural killer cell activity and immunoglobulin synthesis in vitro in aplastic anemia. Acta Med Scand. 1988;224:391–397
  13. Taga T, Kariya Y, Shimada M, Uchida A. Suppression of natural killer cell activity by granulocytes in patients with aplastic anemia: role of granulocyte colony-stimulating factor. Immunol Lett. 1993;39:65–70
  14. Zeng W, Maciejewski JP, Chen G, Risitano AM, Kirby M, Kajigaya S, et al. Selective reduction of natural killer T cells in the bone marrow of aplastic anaemia. Br J Haematol. 2002;119:803–809
  15. Wang Y, Hu X, Guo C, Zhang Q, Peng J, Zhang J, et al. Polarization of natural killer T cells towards an NKT2 subpopulation occurs after stimulation with alpha-galactosylceramide and rhG-CSF in aplastic anemia. Acta Haematol. 2008;119:178–186
  16. Maciejewski JP, Hibbs JR, Anderson S, Katevas P, Young NS. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol. 1994;22:1102–1110
  17. Tu MF, Shao ZH, Liu H, He GS, Shi J, Bai J, et al. Study on the peripheral blood dendritic cells subtypes and the expression of co-stimulating molecules on dendritic cells and B cells in severe aplastic anemia patients. Zhonghua Xue Ye Xue Za Zhi. 2006;27:611–615
  18. He GS, Shao ZH, He H, Liu H, Fu R, Bai J, et al. Changes of subsets of DC1 in the bone marrow of severe aplastic anemia patients. Zhonghua Xue Ye Xue Za Zhi. 2004;25:649–652
  19. Wang J, Shao ZH, Fu R, Ruan EB, Qu W, Liang Y, et al. Study on the dendritic cell subsets in peripheral blood and its relationship with the expressions of T-bet and GATA-3 in lymphocytes in severe aplastic anemia. Zhonghua Xue Ye Xue Za Zhi. 2008;29:733–736
  20. Mentzel U, Vogt H, Rossol R, Geissler RG, Maurer A, Ganser A, et al. Analysis of lymphocyte subsets in patients with aplastic anemia before and during immunosuppressive therapy. Ann Hematol. 1993;66:127–129
  21. Maciejewski JP, Risitano A, Kook H, Zeng W, Chen G, Young NS. Immune pathophysiology of aplastic anemia. Int J Hematol. 2002;76(Suppl. 1):207–214
  22. de Planque MM, Brand A, Kluin-Nelemans HC, Eernisse JG, van der Burgh F, Natarajan AT, et al. Haematopoietic and immunologic abnormalities in severe aplastic anaemia patients treated with anti-thymocyte globulin. Br J Haematol. 1989;71:421–430
  23. Falcao RP, Voltarelli JC, Bottura C. Some immunological studies in aplastic anaemia. J Clin Lab Immunol. 1983;10:25–28
  24. Sabbe LJ, Haak HL, Te Velde J, Bradley BA, de Bode L, Blom J, et al. Immunological investigations in aplastic anemia patients. Acta Haematol. 1984;71:178–188
  25. Callera F, Garcia AB, Falcao RP. Fas-mediated apoptosis with normal expression of bcl-2 and p53 in lymphocytes from aplastic anaemia. Br J Haematol. 1998;100:698–703
  26. Faisal M, Cumberland W, Champlin R, Fahey JL. Effect of recombinant human granulocyte-macrophage colony-stimulating factor administration on the lymphocyte subsets of patients with refractory aplastic anemia. Blood. 1990;76:1580–1585
  27. Lum LG, Seigneuret MC, Doney KC, Storb R. In vitro immunoglobulin production, proliferation, and cell markers before and after antithymocyte globulin therapy in patients with aplastic anemia. Am J Hematol. 1987;26:1–15
  28. Hirano N, Butler MO, Von Bergwelt-Baildon MS, Maecker B, Schultze JL, O’Connor KC, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003;102:4567–4575
  29. Feng X, Chuhjo T, Sugimori C, Kotani T, Lu X, Takami A, et al. Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood. 2004;104:2425–2431
  30. Takamatsu H, Feng X, Chuhjo T, Lu X, Sugimori C, Okawa K, et al. Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood. 2007;109:2514–2520
  31. Takamatsu H, Espinoza JL, Lu X, Qi Z, Okawa K, Nakao S. Anti-moesin antibodies in the serum of patients with aplastic anemia stimulate peripheral blood mononuclear cells to secrete TNF-alpha and IFN-gamma. J Immunol. 2009;182:703–710
  32. Melenhorst JJ, van Krieken JH, Dreef E, Landegent JE, Willemze R, Fibbe WE. T cells selectively infiltrate bone marrow areas with residual haemopoiesis of patients with acquired aplastic anaemia. Br J Haematol. 1997;99:517–519
  33. Zoumbos NC, Ferris WO, Hsu SM, Goodman S, Griffith P, Sharrow SO, et al. Analysis of lymphocyte subsets in patients with aplastic anaemia. Br J Haematol. 1984;58:95–105
  34. Zeng W, Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest. 2001;108:765–773
  35. Zeng W, Nakao S, Takamatsu H, Yachie A, Takami A, Kondo Y, et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood. 1999;93:3008–3016
  36. Melenhorst JJ, Fibbe WE, Struyk L, van der Elsen PJ, Willemze R, Landegent JE. Analysis of T-cell clonality in bone marrow of patients with acquired aplastic anaemia. Br J Haematol. 1997;96:85–91
  37. Nakao S, Yamaguchi M, Shiobara S, Yokoi T, Miyawaki T, Taniguchi T, et al. Interferon-gamma gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia. Blood. 1992;79:2532–2535
  38. Nistico A, Young NS. gamma-Interferon gene expression in the bone marrow of patients with aplastic anemia. Ann Intern Med. 1994;120:463–469
  39. Franzke A, Geffers R, Hunger JK, Pfortner S, Piao W, Ivanyi P, et al. Identification of novel regulators in T-cell differentiation of aplastic anemia patients. BMC Genomics. 2006;7:263
  40. Zeng W, Kajigaya S, Chen G, Risitano AM, Nunez O, Young NS. Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients. Exp Hematol. 2004;32:806–814
  41. Giannakoulas NC, Karakantza M, Theodorou GL, Pagoni M, Galanopoulos A, Kakagianni T, et al. Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients. Br J Haematol. 2004;124:97–105
  42. Solomou EE, Keyvanfar K, Young NS. T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood. 2006;107:3983–3991
  43. Zhang J, Gu Y, Xu C, Qu X. Increased T cell immunoglobulin mucin-3 and its ligand in acquired aplastic anemia. Eur J Haematol. 2008;81:130–139
  44. Nakao S, Takamatsu H, Yachie A, Itoh T, Yamaguchi M, Ueda M, et al. Establishment of a CD4+ T cell clone recognizing autologous hematopoietic progenitor cells from a patient with immune-mediated aplastic anemia. Exp Hematol. 1995;23:433–438
  45. Zoumbos NC, Gascon P, Djeu JY, Trost SR, Young NS. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med. 1985;312:257–265
  46. Solomou EE, Gibellini F, Stewart B, Malide D, Berg M, Visconte V, et al. Perforin gene mutations in patients with acquired aplastic anemia. Blood. 2007;109:5234–5237
  47. Solomou EE, Rezvani K, Mielke S, Malide D, Keyvanfar K, Visconte V, et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood. 2007;110:1603–1606
  48. Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci U S A. 1985;82:188–192
  49. Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002;100:1185–1191
  50. Dubey S, Shukla P, Nityanand S. Expression of interferon-gamma and tumor necrosis factor-alpha in bone marrow T cells and their levels in bone marrow plasma in patients with aplastic anemia. Ann Hematol. 2005;84:572–577
  51. Dufour C, Corcione A, Svahn J, Haupt R, Battilana N, Pistoia V. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol. 2001;115:1023–1031
  52. Rose DM, Winston BW, Chan ED, Riches DW, Henson PM. Interferon-gamma and transforming growth factor-beta modulate the activation of mitogen-activated protein kinases and tumor necrosis factor-alpha production induced by Fc gamma-receptor stimulation in murine macrophages. Biochem Biophys Res Commun. 1997;238:256–260
  53. Kakagianni T, Giannakoulas NC, Thanopoulou E, Galani A, Michalopoulou S, Kouraklis-Symeonidis A, et al. A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients. Leuk Res. 2006;30:713–721
  54. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85:3183–3190
  55. Verma A, Deb DK, Sassano A, Kambhampati S, Wickrema A, Uddin S, et al. Cutting edge: activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hemopoietic suppression in aplastic anemia. J Immunol. 2002;168:5984–5988
  56. Schultz JC, Shahidi NT. Detection of tumor necrosis factor-alpha in bone marrow plasma and peripheral blood plasma from patients with aplastic anemia. Am J Hematol. 1994;45:32–38
  57. Hsu HC, Tsai WH, Chen LY, Hsu ML, Ho CH, Lin CK, et al. Overproduction of inhibitory hematopoietic cytokines by lipopolysaccharide-activated peripheral blood mononuclear cells in patients with aplastic anemia. Ann Hematol. 1995;71:281–286
  58. Hsu HC, Tsai WH, Chen LY, Hsu ML, Ing-Tiau Kuo B, Ho CH, et al. Production of hematopoietic regulatory cytokines by peripheral blood mononuclear cells in patients with aplastic anemia. Exp Hematol. 1996;24:31–36
  59. Hara T, Ando K, Tsurumi H, Moriwaki H. Excessive production of tumor necrosis factor-alpha by bone marrow T lymphocytes is essential in causing bone marrow failure in patients with aplastic anemia. Eur J Haematol. 2004;73:10–16
  60. Kasahara S, Hara T, Itoh H, Ando K, Tsurumi H, Sawada M, et al. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor. Br J Haematol. 2002;118:181–188
  61. Demeter J, Messer G, Schrezenmeier H. Clinical relevance of the TNF-alpha promoter/enhancer polymorphism in patients with aplastic anemia. Ann Hematol. 2002;81:566–569
  62. Gascon P, Scala G. Decreased interleukin-1 production in aplastic anemia. Am J Med. 1988;85:668–674
  63. Nakao S, Matsushima K, Young N. Decreased interleukin 1 production in aplastic anaemia. Br J Haematol. 1989;71:431–436
  64. Holmberg LA, Seidel K, Leisenring W, Torok-Storb B. Aplastic anemia: analysis of stromal cell function in long-term marrow cultures. Blood. 1994;84:3685–3690
  65. Kawano Y, Takaue Y, Hirao A, Watanabe T, Abe T, Shimizu T, et al. Production of interleukin 3 and granulocyte-macrophage colony-stimulating factor from stimulated blood mononuclear cells in patients with aplastic anemia. Exp Hematol. 1992;20:1125–1128
  66. Gibson FM, Scopes J, Daly S, Ball S, Gordon-Smith EC. Haemopoietic growth factor production by normal and aplastic anaemia stroma in long-term bone marrow culture. Br J Haematol. 1995;91:551–561
  67. Cockrell EM, Gorman J, Hord JD. Endogenous interleukin-11 (IL-11) levels in newly diagnosed children with acquired severe aplastic anemia (SAA). Cytokine. 2004;28:55–58
  68. Gascon P, Zoumbos NC, Scala G, Djeu JY, Moore JG, Young NS. Lymphokine abnormalities in aplastic anemia: implications for the mechanism of action of antithymocyte globulin. Blood. 1985;65:407–413
  69. Nissen C, Moser Y, Weis J, Wursch A, Gratwohl A, Speck B. The release of interleukin-2 (IL-2) and colony stimulating activity (CSA) in aplastic anemia patients: opposite behaviour with improvement of bone marrow function. Blut. 1986;52:221–230
  70. Gu Y, Hu X, Liu C, Qv X, Xu C. Interleukin (IL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia. Br J Haematol. 2008;142:109–114
  71. Tripathy NK, Nityanand S. Bone marrow and blood plasma levels of IL-8 in aplastic anemia and their relationship with disease severity. Am J Hematol. 2005;79:240–242
  72. Gu Y, Zhang J, Peng J, Hu X, Xu C. Elevated expression of IL-12 and IL-23 in patients with aplastic anemia. Int J Lab Hematol. 2009;31:207–214
  73. Dirksen U, Asadi-Moghaddam K, Fuhrer M, Burdach S. Defunct hematopoietic progenitor growth and heterogeneous immunological phenotypes in acquired aplastic anemia of childhood: identification of subsets with decreased hematopoietic progenitors and increased IL15 or IL10 production. Klin Padiatr. 1998;210:167–172
  74. Wenxin L, Jinxiang F, Yong W, Wenxiang L, Wenbiao S, Xueguang Z. Expression of membrane-bound IL-15 by bone marrow fibroblast-like stromal cells in aplastic anemia. Int Immunol. 2005;17:429–437
  75. Dilloo D, Vohringer R, Josting A, Habersang K, Scheidt A, Burdach S. Bone marrow fibroblasts from children with aplastic anemia exhibit reduced interleukin-6 production in response to cytokines and viral challenge. Pediatr Res. 1995;38:716–721
  76. Mayer A, Podlech J, Kurz S, Steffens HP, Maiberger S, Thalmeier K, et al. Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes. J Virol. 1997;71:4589–4598
  77. Kojima S, Matsuyama T, Kodera Y. Hematopoietic growth factors released by marrow stromal cells from patients with aplastic anemia. Blood. 1992;79:2256–2261
  78. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–2147
  79. Brugger W, Mocklin W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood. 1993;81:2579–2584
  80. Jacobsen SE, Ruscetti FW, Okkenhaug C, Lien E, Ortiz M, Veiby OP, et al. Distinct and direct synergistic effects of IL-1 and IL-6 on proliferation and differentiation of primitive murine hematopoietic progenitor cells in vitro. Exp Hematol. 1994;22:1064–1069
  81. Farese AM, Williams DE, Seiler FR, MacVittie TJ. Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage colony-stimulating factor in a primate model of radiation-induced marrow aplasia. Blood. 1993;82:3012–3018
  82. Lindemann A, Mertelsmann R. Interleukin-3 and its receptor. Cancer Treat Res. 1995;80:107–142
  83. Eder M, Geissler G, Ganser A. IL-3 in the clinic. Stem Cells. 1997;15:327–333
  84. Metcalf D, Begley CG, Johnson GR, Nicola NA, Lopez AF, Williamson DJ. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood. 1986;68:46–57
  85. Kaushansky K, Thrombopoietin . N Engl J Med. 1998;339:746–754
  86. Kurzrock R. Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited. Clin Cancer Res. 2005;11:1361–1367
  87. Cork BA, Tuckerman EM, Li TC, Laird SM. Expression of interleukin (IL)-11 receptor by the human endometrium in vivo and effects of IL-11, IL-6 and LIF on the production of MMP and cytokines by human endometrial cells in vitro. Mol Hum Reprod. 2002;8:841–848
  88. Wu HH, Talpaz M, Champlin RE, Pilat SR, Kurzrock R. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer. 2003;98:2410–2419
  89. Raghavachar A, Ganser A, Freund M, Heimpel H, Herrmann F, Schrezenmeier H. Long-term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia. Cytokines Mol Ther. 1996;2:215–223
  90. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 2001;19:4165–4172
  91. Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. Ann Oncol. 2005;16:139–145
  92. Walsh CE, Liu JM, Anderson SM, Rossio JL, Nienhuis AW, Young NS. A trial of recombinant human interleukin-1 in patients with severe refractory aplastic anaemia. Br J Haematol. 1992;80:106–110
  93. Nemunaitis J, Ross M, Meisenberg B, O’Reilly R, Lilleby K, Buckner CD, et al. Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure. Bone Marrow Transplant. 1994;14:583–588
  94. Ganser A, Lindemann A, Seipelt G, Ottmann OG, Eder M, Falk S, et al. Effects of recombinant human interleukin-3 in aplastic anemia. Blood. 1990;76:1287–1292
  95. Kishimoto T. The biology of interleukin-6. Blood. 1989;74:1–10
  96. Ulich TR, del Castillo J, Guo KZ. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood. 1989;73:108–110
  97. Carrington PA, Hill RJ, Stenberg PE, Levin J, Corash L, Schreurs J, et al. Multiple in vivo effects of interleukin-3 and interleukin-6 on murine megakaryocytopoiesis. Blood. 1991;77:34–41
  98. Schrezenmeier H, Marsh JC, Stromeyer P, Muller H, Heimpel H, Gordon-Smith EC, et al. A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anaemia. Br J Haematol. 1995;90:283–292
  99. Fermo E, Bianchi P, Barcellini W, Pedotti P, Boschetti C, Alfinito F, et al. Immunoregulatory cytokine polymorphisms in Italian patients affected by paroxysmal nocturnal haemoglobinuria and aplastic anaemia. Eur J Immunogenet. 2004;31:267–269
  100. Gidvani V, Ramkissoon S, Sloand EM, Young NS. Cytokine gene polymorphisms in acquired bone marrow failure. Am J Hematol. 2007;82:721–724
  101. Hinterberger W, Adolf G, Bettelheim P, Geissler K, Huber C, Irschick E, et al. Lymphokine overproduction in severe aplastic anemia is not related to blood transfusions. Blood. 1989;74:2713–2717
  102. Azogui O, Gluckman E, Fradelizi D. Inhibiton of IL 2 production after human allogeneic bone marrow transplantation. J Immunol. 1983;131:1205–1208
  103. Platanias L, Gascon P, Bielory L, Griffith P, Nienhuis A, Young N. Lymphocyte phenotype and lymphokines following anti-thymocyte globulin therapy in patients with aplastic anaemia. Br J Haematol. 1987;66:437–443
  104. Maciejewski JP, Sloand EM, Nunez O, Boss C, Young NS. Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood. 2003;102:3584–3586
  105. Geissler K, Kabrna E, Kollars M, Ohler L, Berer A, Burgmann H, et al. Interleukin-10 inhibits in vitro hematopoietic suppression and production of interferon-gamma and tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with aplastic anemia. Hematol J. 2002;3:206–213
  106. Asano Y, Shibata S, Kobayashi S, Okamura S, Niho Y. Effect of interleukin 10 on the hematopoietic progenitor cells from patients with aplastic anemia. Stem Cells. 1999;17:147–151
  107. Maciejewski JP, Liu JM, Green SW, Walsh CE, Plumb M, Pragnell IB, et al. Expression of stem cell inhibitor (SCI) gene in patients with bone marrow failure. Exp Hematol. 1992;20:1112–1117
  108. Taketazu F, Miyagawa K, Ichijo H, Oshimi K, Mizoguchi H, Hirai H, et al. Decreased level of transforming growth factor-beta in blood lymphocytes of patients with aplastic anemia. Growth Factors. 1992;6:85–90
  109. Rizzo S, Killick SB, Patel S, Ball SE, Wadhwa M, Dilger P, et al. Reduced TGF-beta1 in patients with aplastic anaemia in vivo and in vitro. Br J Haematol. 1999;107:797–803
  110. Wodnar-Filipowicz A, Yancik S, Moser Y, dalle Carbonare V, Gratwohl A, Tichelli A, et al. Levels of soluble stem cell factor in serum of patients with aplastic anemia. Blood. 1993;81:3259–3264
  111. Das RE, Milne A, Rowley M, Smith EC, Cotes PM. Serum immunoreactive erythropoietin in patients with idiopathic aplastic and Fanconi's anaemias. Br J Haematol. 1992;82:601–607
  112. Schrezenmeier H, Noe G, Raghavachar A, Rich IN, Heimpel H, Kubanek B. Serum erythropoietin and serum transferrin receptor levels in aplastic anaemia. Br J Haematol. 1994;88:286–294
  113. Marsh JC, Gibson FM, Prue RL, Bowen A, Dunn VT, Hornkohl AC, et al. Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol. 1996;95:605–610
  114. Schrezenmeier H, Griesshammer M, Hornkohl A, Nichol JL, Hecht T, Heimpel H, et al. Thrombopoietin serum levels in patients with aplastic anaemia: correlation with platelet count and persistent elevation in remission. Br J Haematol. 1998;100:571–576
  115. Kojima S, Matsuyama T, Kodera Y, Tahara T, Kato T. Measurement of endogenous plasma thrombopoietin in patients with acquired aplastic anaemia by a sensitive enzyme-linked immunosorbent assay. Br J Haematol. 1997;97:538–543
  116. Watari K, Asano S, Shirafuji N, Kodo H, Ozawa K, Takaku F, et al. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood. 1989;73:117–122
  117. Xu H, Li A, Yu Y, Li J, Liu X, Wang X, et al. Comparative analysis of G-CSFR and GM-CSFR expressions on CD(34)(+) cells in patients with aplastic anemia and myelodysplastic syndrome. Int J Lab Hematol. 2008;
  118. Marsh JC, Ganser A, Stadler M. Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Semin Hematol. 2007;44:138–147
  119. Li Z, Li L. Understanding hematopoietic stem-cell microenvironments. Trends Biochem Sci. 2006;31:589–595
  120. Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia. 2008;22:941–950
  121. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood. 1996;88:1983–1991
  122. Podesta M, Piaggio G, Frassoni F, Pitto A, Zikos P, Sessarego M, et al. The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia. Blood. 1998;91:1959–1965
  123. Rizzo S, Scopes J, Elebute MO, Papadaki HA, Gordon-Smith EC, Gibson FM. Stem cell defect in aplastic anemia: reduced long term culture-initiating cells (LTC-IC) in CD34+ cells isolated from aplastic anemia patient bone marrow. Hematol J. 2002;3:230–236
  124. Manz CY, Nissen C, Wodnar-Filipowicz A. Deficiency of CD34+ c-kit+ and CD34+38- hematopoietic precursors in aplastic anemia after immunosuppressive treatment. Am J Hematol. 1996;52:264–274
  125. Rizzo S, Scopes J, Draycott GS, Pocock C, Foukaneli T, Rutherford TR, et al. Quiescent (5-fluorouracil-resistant) aplastic anemia hematopoietic cells in vitro. Exp Hematol. 2004;32:665–672
  126. Matsui WH, Brodsky RA, Smith BD, Borowitz MJ, Jones RJ. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia. 2006;20:458–462
  127. Scopes J, Daly S, Atkinson R, Ball SE, Gordon-Smith EC, Gibson FM. Aplastic anemia: evidence for dysfunctional bone marrow progenitor cells and the corrective effect of granulocyte colony-stimulating factor in vitro. Blood. 1996;87:3179–3185
  128. Schrezenmeier H, Jenal M, Herrmann F, Heimpel H, Raghavachar A. Quantitative analysis of cobblestone area-forming cells in bone marrow of patients with aplastic anemia by limiting dilution assay. Blood. 1996;88:4474–4480
  129. Bacigalupo A, Piaggio G, Podesta M, Tong J, Pitto A, Figari O, et al. Early hemopoietic progenitors in the peripheral blood of patients with severe aplastic anemia (SAA) after treatment with antilymphocyte globulin (ALG), cyclosporin-A and G-CSF. Haematologica. 1997;82:133–137
  130. Cox CV, Killick SB, Patel S, Elebute MO, Marsh JC, Gordon-Smith EC, et al. In vitro proliferation and differentiation of megakaryocytic progenitors in patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria, and the myelodysplastic syndromes. Stem Cells (Dayton, Ohio). 2000;18:428–434
  131. Marsh JC, Chang J, Testa NG, Hows JM, Dexter TM. The hematopoietic defect in aplastic anemia assessed by long-term marrow culture. Blood. 1990;76:1748–1757
  132. Bacigalupo A, Figari O, Tong J, Piaggio G, Miceli S, Frassoni F, et al. Long-term marrow culture in patients with aplastic anemia compared with marrow transplant recipients and normal controls. Exp Hematol. 1992;20:425–430
  133. Scopes J, Bagnara M, Gordon-Smith EC, Ball SE, Gibson FM. Haemopoietic progenitor cells are reduced in aplastic anaemia. Br J Haematol. 1994;86:427–430
  134. Philpott NJ, Scopes J, Marsh JC, Gordon-Smith EC, Gibson FM. Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Exp Hematol. 1995;23:1642–1648
  135. Timeus F, Crescenzio N, Doria A, Foglia L, Linari A, Giaccone M, et al. Flow cytometric evaluation of circulating CD34+ cell counts and apoptotic rate in children with acquired aplastic anemia and myelodysplasia. Exp Hematol. 2005;33:597–604
  136. Callera F, Falcao RP. Increased apoptotic cells in bone marrow biopsies from patients with aplastic anaemia. Br J Haematol. 1997;98:18–20
  137. Killick SB, Cox CV, Marsh JC, Gordon-Smith EC, Gibson FM. Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti-thymocyte globulin: examination of the role of the Fas-Fas-L interaction. Br J Haematol. 2000;111:1164–1169
  138. Zeng W, Chen G, Kajigaya S, Nunez O, Charrow A, Billings EM, et al. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood. 2004;103:325–332
  139. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol. 1995;91:245–252
  140. Ismail M, Gibson FM, Gordon-Smith EC, Rutherford TR. Bcl-2 and Bcl-x expression in the CD34+ cells of aplastic anaemia patients: relationship with increased apoptosis and upregulation of Fas antigen. Br J Haematol. 2001;113:706–712
  141. Calado RT, Garcia AB, Gallo DA, Falcao RP. Reduced function of the multidrug resistance P-glycoprotein in CD34+ cells of patients with aplastic anaemia. Br J Haematol. 2002;118:320–326
  142. Kaito K, Otsubo H, Ogasawara Y, Shimada T, Usui N, Kobayashi M. Adhesion molecule expression by bone marrow CD34-positive cells in aplastic anemia before and after immunosuppressive therapy. Clin Lab Haematol. 2003;25:393–396
  143. Fujimaki S, Harigae H, Sugawara T, Takasawa N, Sasaki T, Kaku M. Decreased expression of transcription factor GATA-2 in haematopoietic stem cells in patients with aplastic anaemia. Br J Haematol. 2001;113:52–57
  144. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood. 1998;91:3582–3592
  145. Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001;97:895–900
  146. Calado RT, Young NS. Telomere maintenance and human bone marrow failure. Blood. 2008;111:4446–4455
  147. Fogarty PF, Yamaguchi H, Wiestner A, Baerlocher GM, Sloand E, Zeng WS, et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet. 2003;362:1628–1630
  148. Yamaguchi H. Mutations of telomerase complex genes linked to bone marrow failures. J Nippon Med Sch = Nihon Ika Daigaku zasshi. 2007;74:202–209
  149. Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352:1413–1424
  150. Savage SA, Calado RT, Xin ZT, Ly H, Young NS, Chanock SJ. Genetic variation in telomeric repeat binding factors 1 and 2 in aplastic anemia. Exp Hematol. 2006;34:664–671
  151. Islam A. Do bone marrow fat cells or their precursors have a pathogenic role in idiopathic aplastic anaemia?. Med Hypotheses. 1988;25:209–217
  152. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007;21:1733–1738
  153. Fang B, Li N, Song Y, Li J, Zhao RC, Ma Y. Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia. Pediatr Transplant. 2008;
  154. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev. 2008;8:726–736
  155. Juneja HS, Gardner FH. Functionally abnormal marrow stromal cells in aplastic anemia. Exp Hematol. 1985;13:194–199
  156. Xu Y, Takahashi Y, Wang Y, Hama A, Nishio N, Muramatsu H, et al. Downregulation of GATA-2 and overexpression of adipogenic gene-PPARgamma in mesenchymal stem cells from patients with aplastic anemia. Exp Hematol. 2009;37:1393–1399
  157. Wang HY, Ding TL, Xie Y, Xu XP, Yu L, Chen T. Osteogenic and adipogenic differentiation of bone marrow-derived mesenchymal stem cells in patients with aplastic anemia. Zhonghua Nei Ke Za Zhi. 2009;48:39–43
  158. Wu X, Li Y, Zhu K, Wang Z, Chen S, Yang L. GATA-1, -2 and -3 genes expression in bone marrow microenviroment with chronic aplastic anemia. Hematology. 2007;12:331–335
  159. Bacigalupo A, Valle M, Podesta M, Pitto A, Zocchi E, De Flora A, et al. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp Hematol. 2005;33:819–827
  160. Chen J, Lipovsky K, Ellison FM, Calado RT, Young NS. Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure. Blood. 2004;104:1671–1678
  161. Scopes J, Ismail M, Marks KJ, Rutherford TR, Draycott GS, Pocock C, et al. Correction of stromal cell defect after bone marrow transplantation in aplastic anaemia. Br J Haematol. 2001;115:642–652
  162. Fouillard L, Bensidhoum M, Bories D, Bonte H, Lopez M, Moseley AM, et al. Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia. 2003;17:474–476
  163. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004;95:343–353
  164. Schatteman GC, Awad O. Hemangioblasts, angioblasts, and adult endothelial cell progenitors. Anat Rec A Discov Mol Cell Evol Biol. 2004;276:13–21
  165. Fureder W, Krauth MT, Sperr WR, Sonneck K, Simonitsch-Klupp I, Mullauer L, et al. Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia. Am J Pathol. 2006;168:123–130
  166. Gupta P, Khurana N, Singh T, Gupta D, Dhingra KK. Bone marrow angiogenesis in aplastic anemia--a study of CD 34 and VEGF expression in bone marrow biopsies. Hematology. 2009;14:16–21
  167. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96:3374–3380
  168. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240–2245
  169. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318:1920–1923
  170. Ye L, Chang JC, Lin C, Sun X, Yu J, Kan YW. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci U S A. 2009;106:9826–9830
  171. Raya A, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S, Barrero MJ, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009;460:53–59

PII: S1040-8428(09)00246-7

doi: 10.1016/j.critrevonc.2009.12.001

Critical Reviews in Oncology / Hematology
Volume 75, Issue 2 , Pages 79-93 , August 2010

Article Tools

* Image Usage & Resolution